Drug intelligence / Profile preview

BBO-11818 + pembrolizumab + cisplatin + pemetrexed

Development stage: Unknown
Lead developer: BridgeBio Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination regimen investigated for advanced cancers with KRAS mutations, specifically **non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC)**. BBO-11818 is a first-in-class **pan-KRAS inhibitor** that targets multiple mutant KRAS proteins, including KRAS G12D and G12V, by disrupting oncogenic KRAS signaling. Pembrolizumab is an **anti–PD-1 monoclonal antibody** (immunotherapy), cisplatin is a **DNA crosslinking platinum chemotherapy**, and pemetrexed is an **antifolate chemotherapy** that inhibits thymidylate synthase and other enzymes. The combination aims to both block oncogenic signaling and leverage immune checkpoint blockade along with cytotoxic chemotherapy to maximize antitumor effect. This combination is in phase 1 clinical evaluation for patients with unresectable or metastatic KRAS-mutant solid tumors, with dose escalation and expansion cohorts to establish safety and antitumor activity[1][3][5][7].

Brand names: Keytruda (for pembrolizumab)Alimta (for pemetrexed)Platinol (for cisplatin)
Other names: BBO-11818 + pembrolizumab + cisplatin + pemetrexed

Targets

PDCD1 (Programmed cell death protein 1 receptor)KRAS (Kirsten rat sarcoma viral oncogene homolog)TS (Thymidylate synthase)DNA

Beyond the preview

Go deeper on BBO-11818 + pembrolizumab + cisplatin + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBO-11818 + pembrolizumab + cisplatin + pemetrexed.

Explore the full profile